Hemosorbent

EnterosorbU for hemosorbent applications is specifically designed to adsorb inflammatory mediators and cytokines to treat sepsis, a disease resulting from the body's inflammatory response to severe infection. Sepsis affects over 20 million people worldwide each year and kills around 500,000 of them. EnterosorbU intended for sepsis is mesoporous in nature with slit-like open pore structure enabling the adsorption of cytokines to occur throughout the bulk of the material. It has a particle size of 100 microns, pore size of 5-10 nm, pore volume of over 1.0 cm³/g and a surface area over 1000 m²/g.

EnterosorbU is available in the bulk form that can be packed in hemofiltration cartridges used for extracorporeal organ assist devices.   

Additionally, we have the capability of tuning the properties of EnterosorbU for the adsorption of specific biomolecules. If you need help in selecting the right sorbent for adsorption of specific molecule then please write us.

Cytokine adsorption

Severe and uncontrolled microbial infection often results in septicemia, causing septic shock and subsequent organ failure. This process leads to death from kidney and liver failure. Presence of growing amounts of various inflammatory mediators (cytokines) leads to sepsis. We performed the adsorption of 42 cytokines for 5, 30 and 60 minutes on one of our carbons. The results of the adsorption test is shown below.

Method

Fresh frozen human plasma was defrosted and spiked with a standard cytokine solution containing 42 cytokines at concentration of about 1000 pg/ml. Carbon adsorbents (0.02 g, particle size: 40/60 mesh) were equilibrated in phosphate-buffered saline (PBS) (0.5 ml) overnight prior to removal of PBS and addition of 800 ml of spiked human plasma. Controls consisted of spiked and un-spiked plasma with no adsorbent present. The samples were incubated at 37oC while shaking (90 rpm). After 5, 30 and 60 minutes of exposure times, the samples were centrifuged, and the 100 µl of supernatant was collected for analysis by enzyme-linked immunosorbent assay (ELISA) using multiplex kits for human 42-plex cytokines.

Results and discussion

The EnterosorbU tested here showed excellent cytokine adsorption capability within one hour. The small molecular weight cytokines (10-15 kDa) like IL-1, IL-2, etc. showed 70-90% removal within 60 min, medium molecular weight cytokines (15-20 kDa) like TNF-alpha, IL-10, etc. showed 50-70% removal within 60 minutes and large molucules like IL-5, IL-6, VEGF demonstrated 20-50% removal in 60 minutes. There are many factors affecting the adsorption kinetics of biomolecules including their molecular weight, hydrodynamic radius, charge, polarity, etc. We can tune the sorbent properties necessary for optimal adsorption for a given set of cytokines. The experiment was conducted on a set of 42 cytokines. The adsorption kinetics will alter if less or more number of cytokines are used. It is expected that the cytokine adsorption will be higher and faster if a smaller number of cytokines are used.

Customized products

Need help determining which material best suits your application? Please give us a call at 215-788-2461 or email us at sThis email address is being protected from spambots. You need JavaScript enabled to view it. . While companies using porous carbon can choose from hundreds of off-the-shelf commodity products, Carbon-Ukraine offers a new option: carbons whose properties are rapidly tuned for a specific application.

We are interested in partnering with end-users to develop carbons specifically tailored to meet their needs. Normally, when developing materials for a new application we will begin by thoroughly studying the underlying technology and the key materials properties required. Once we have an understanding of the materials properties required, we can provide small quantities of material for evaluation. Based on the results of your evaluation, we can provide additional samples to further optimize our materials for your application. 

Important notice regarding this product

EnterosorbU is a product of Carbon-Ukraine, ltd. The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, Carbon-Ukraine, ltd. expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. The information contained in this document is based on tests conducted by Carbon-Ukraine, ltd. and data selected from the literature, but shall in no event be held to constitute or imply any warranty, undertaking, express or implied commitment from our part.

Our formal specifications define the limit of our commitment. Carbon-Ukraine, ltd. can accept no liability whatsoever with regard to the handling, processing or use of the product or products concerned which must in all cases be employed in accordance with all relevant laws and/or regulations in force in the country or countries concerned. EnterosorbU is currently available ONLY for research and development purpose and thus should not be used for any medical use.